Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA advisory committee cuts

This article was originally published in The Tan Sheet

Executive Summary

HHS expects to submit to OMB on May 24 recommendations on how FDA's advisory committee system can be downsized. The recommendations are being made in response to an executive order asking that each federal department and agency terminate not less than one-third of its advisory committees. Groups including NDMA and APhA have sent letters to FDA urging that the OTC Drugs Advisory Committee and other FDA advisory panels not be dismantled ("The Tan Sheet" May 3, p. 13).
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel